Bococizumab

Phase 3Monoclonal antibody

Pfizer

Bococizumab is one of 77 small molecule programs targeting Hyperlipidemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperlipidemiaActive, not recruiting

Familial HypercholesterolemiaActive, not recruiting

HypercholesterolemiaActive, not recruiting

HyperlipidemiaPhase 3

Active, not recruiting

Familial HypercholesterolemiaPhase 3

Active, not recruiting

HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

130 competitors in Hypercholesterolemia

#DrugCompanyPhaseTrials

Avapro

Sanofi

Phase 3

1 2

Micardis

Boehringer Ingelheim

Phase 3

1 3

Comparator: Statins

Merck & Co.

Phase 3

3 4

Statin

Bristol-Myers Squibb

Phase 3

2 5

Kynamro

KKastle Therapeutics, LLC

Phase 3

1 6

Enlicitide

Merck & Co.

Phase 3

3 7

Anacetrapib

Merck & Co.

Phase 3

1 8

Lapaquistat Acetate

Takeda

Phase 3

9 9

Lipid-Modifying Therapy (LMT)

Sanofi

Phase 3

5 10

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperlipidemia4 trials

Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia

Completed· Pfizer logo

Pfizer·Phase 3·NCT02458287·299 enrolled

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Completed· Pfizer logo

Pfizer·Phase 3·NCT01968967·2,139 enrolled

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Completed· Pfizer logo

Pfizer·Phase 3·NCT02100514·746 enrolled

Show 1 more trial

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Completed· Pfizer logo

Pfizer·Phase 3·NCT01968954·711 enrolled

Major Cardiovascular Event2 trials

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01975376·16,784 enrolled

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Terminated· Pfizer logo

Pfizer·Phase 3·NCT01975389·10,564 enrolled

Hypercholesterolemia1 trial

Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

Withdrawn· Pfizer logo

Pfizer·Phase 3·NCT02947334

Clinical Trial1 trial

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Completed· Pfizer logo

Pfizer·Phase 3·NCT02135029·184 enrolled

Cholesterol1 trial

Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

Completed· Pfizer logo

Pfizer·Phase 2·NCT02055976·218 enrolled

4 more indications

Familial Hypercholesterolemia1 trial

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Completed· Pfizer logo

Pfizer·Phase 3·NCT01968980·370 enrolled

Tics1 trial

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Completed· Pfizer logo

Pfizer·Phase 1·NCT02043301·75 enrolled

HIV1 trial

Bococizumab HIV Evaluation (B-HIVE) Study

Terminated·UUniversity of California, San Francisco·Phase 3·NCT02524106·11 enrolled

Unspecified1 trial

Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02667223·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Bococizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bococizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bococizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Bococizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperlipidemia4 trials

Major Cardiovascular Event2 trials

Hypercholesterolemia1 trial

Clinical Trial1 trial

Cholesterol1 trial

Familial Hypercholesterolemia1 trial

Tics1 trial

HIV1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News